Recent Quotes (30 days)

You have no recent quotes
chg | %

ZIOPHARM Oncology Inc.  

(Public, NASDAQ:ZIOP)   Watch this stock  
Find more results for ZIOP
4.49
+0.23 (5.40%)
Nov 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.26 - 4.53
52 week 4.03 - 7.88
Open 4.26
Vol / Avg. 0.00/1.92M
Mkt cap 637.41M
P/E     -
Div/yield     -
EPS -0.52
Shares 141.96M
Beta 1.49
Inst. own 50%
Nov 20, 2017
ZIOPHARM Oncology Inc Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting - Call - Webcast
Nov 14, 2017
ZIOPHARM Oncology Inc at Stifel Healthcare Conference
Nov 6, 2017
Q3 2017 ZIOPHARM Oncology Inc Earnings Call - Webcast
Sep 12, 2017
ZIOPHARM Oncology Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -794.81% -2409.23%
Operating margin -818.40% -2409.37%
EBITD margin - -2405.14%
Return on average assets -41.86% -127.12%
Return on average equity - -3423.41%
Employees 36 -
CDP Score - -

Address

One First Avenue Parris Building 34 Navy Yard Plaza
BOSTON, MA 02129
United States - Map
+1-617-2591970 (Phone)
+1-617-2412855 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Officers and directors

Laurence James Neil Cooper M.D., Ph.D. Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Kevin G. Lafond CPA Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 61
Bio & Compensation  - Reuters
David M. Mauney M.D. Interim Chief Operating Officer, Executive Vice President, Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Caesar J. Belbel Executive Vice President, Chief Legal Officer and Secretary
Age: 57
Bio & Compensation  - Reuters
Francois Lebel M.D. Executive Vice President - Research and Development and Chief Medical Officer
Age: 65
Bio & Compensation  - Reuters
Lynn Ferrucci Senior Vice President - Human Resources, Facilities and Administration
Bio & Compensation  - Reuters
David Connolly Vice President - Corporate Communications and Investor Relations
Bio & Compensation  - Reuters
Murray Brennan M.D. Non-Executive Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
Randal J. Kirk Director
Age: 63
Bio & Compensation  - Reuters
James A. Cannon Independent Director
Age: 78
Bio & Compensation  - Reuters